References
- Yeh S. W., Sami N., Ahmed R. A. Treatment of pemphigus vulgaris. Current and emerging options. Am J Clin Dermatol 2005; 6: 327–42
- Reff M., Carner K., Chambers K., Chinn P., Leonard J., Raab R., et al. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–45
- Edwards J. C., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001; 40: 205–11
- Stasi R., Stipa E., Forte V., Meo P., Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002; 99: 3872–3
- Sabugo F., Llanos C., Soto L., Gutierrez J., Cuchacovich M. Uso del rituximab (anticuerpo monoclonal anti‐CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico. Rev Med Chil 2005; 133: 681–4
- Specks U., Fervenza F. C., McDonald T. J., Hogan M. C. Response of Wegener's granulomatosis to anti‐CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44: 2836–40
- Barnadas M. A., Roe E., Brunet S., García P., Bergua P., Pimentel L., et al. Therapy of paraneoplastic pemphigus with rituximab: A case report and review of literature. J Eur Acad Dermatol Venereol 2005; 20: 69–74
- Quartier P., Brethon B., Philippet P., Landman‐Parker J., Le Deist F., Fischer A. Treatment of childhood autoinmune hemolytic anemia with rituximab. Lancet 2001; 358: 1511–13
- Arin M. J., Engert A., Krieg T., Hunzelmann N. Anti‐CD20 monoclonal antibody in the treatment of pemphigus. Br J Dermatol 2005; 153: 620–5
- Schmidt E., Herzog S., Broker E. B., Zillikens D., Goebeler M. Long‐standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 2005; 153: 440–6
- Kong H. H., Prose N. S., Ware R. E., Hall R. P. Successful treatment of refractory childhood pemphigus vulgaris with anti‐CD20 monoclonal antibody (rituximab). Pediatr Dermatol 2005; 22: 461–4
- Cecchi R., Gasperini U. Severe pemphigus vulgaris treated with rituximab (Mabthera). J Dermatol 2005; 32: 86–94
- Wenzel J., Bauer R., Bieber T., Tüting T. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple inmunosuppressants. Acta Derm Venereol 2004; 85: 185–6
- Virgolini V., Marzocchi V. Anti‐CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: Report of a case. Haematologica 2003; 88((7))ELT24
- Herrmann G., Engert A., Hunzelmann N. Treatment of pemphigus vulgaris with anti‐CD20 monoclonal antibody (rituximab). Br J Dermatol 2003; 148: 593–611
- Pitarch G., Sánchez‐Carazo J. L., Pardo J., Torrijos A., Roche E., Fortea J. M. Tratamiento de pénfigo vulgar grave resistente con rituximab. Actas Dermosifiliogr 2006; 97: 48–51
- Domínguez‐Fernández I., Pérez‐Gala S., Goiriz R., Sánchez‐Pérez J., Fernández‐Herrera J. Pemphigus vulgaris treated with rituximab. Actas Dermosifiliogr 2006; 97: 221–2
- El Tal A. K., Posner M. R., Spigelman Z., Ahmed A. R. Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2006; 55: 449–59
- Dupuy A., Viguier M., Bedane C., Cordoliani F., Blaise S., Aucouturier F., et al. Treatment of refractory pemphigus vulgaris with Rituximab (anti‐CD20 monoclonal antibody). Arch Dermatol 2004; 140: 91–6
- Morrison L. H. Therapy of refractory pemphigus vulgaris with monoclonal anti‐CD20 antibody (rituximab). J Am Acad Dermatol 2004; 51: 817–19
- Ghielmini M., Schmitz S. F., Cogliatti S., Pichert G., Hummerjohann J., Waltzer U., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event‐free survival and response duration compared with the standard weekly×4 schedule. Blood 2004; 103: 4416–23